Edition:
India

Indivior PLC (INDV.L)

INDV.L on London Stock Exchange

446.50GBp
23 Apr 2018
Change (% chg)

10.10 (+2.31%)
Prev Close
436.40
Open
438.00
Day's High
447.60
Day's Low
434.80
Volume
2,281,209
Avg. Vol
2,113,094
52-wk High
447.60
52-wk Low
246.50

Chart for

About

Indivior PLC (Indivior) is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence (the Indivior Business). Its treatment and pipeline focus is opioid use disorder, alcohol use disorder, overdose rescue... (more)

Overall

Beta: --
Market Cap(Mil.): £2,498.61
Shares Outstanding(Mil.): 721.46
Dividend: --
Yield (%): --

Financials

  INDV.L Industry Sector
P/E (TTM): 48.23 30.95 32.74
EPS (TTM): 0.07 -- --
ROI: 25.75 14.84 14.38
ROE: -- 16.34 16.07

BRIEF-Indivior Says Filed NDS With Health Canada's For Sublocade Injection

* FILED A NEW DRUG SUBMISSION (NDS) WITH HEALTH CANADA'S THERAPEUTIC DRUGS DIRECTORATE FOR SUBLOCADE INJECTION Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

20 Apr 2018

BRIEF-Indivior Says Filed New Drug Submission With Health Canada For Sublocade Injection

* SAYS FILED A NEW DRUG SUBMISSION (NDS) WITH HEALTH CANADA'S THERAPEUTIC DRUGS DIRECTORATE FOR SUBLOCADE INJECTION

20 Apr 2018

BRIEF-Indivior files lawsuits over Suboxone patent

* HAS FILED PATENT LAWSUITS AGAINST DR. REDDY'S, ACTAVIS, PAR, ALVOGEN AND TEVA FOR INFRINGEMENT OF PATENT RELATING SUBOXONE Source text for Eikon: Further company coverage: (Reporting By London Bureau)

05 Apr 2018

BRIEF-‍Indivior Says Enters Into License Agreement For C4x Discovery's OX1 Antagonist Program​

* ‍INDIVIOR ENTERS INTO AN EXCLUSIVE GLOBAL LICENSE AGREEMENT FOR C4X DISCOVERY'S OREXIN-1 (OX1) ANTAGONIST PROGRAM​

29 Mar 2018

UPDATE 1-Rising trade tensions sends FTSE 100 lower

LONDON, March 23 Mounting fears of a global trade war after the U.S. slapped tariffs on imports from China sent British stocks to a 15-month low on Friday.

23 Mar 2018

Indivior loses another case in battle to protect opioid addiction drug

Shares in Britain's Indivior were hammered on Friday after it lost a second legal case in recent months in its battle to protect the patent of its opioid addiction treatment that generates 80 percent of its revenues.

23 Mar 2018

Escalating trade aggression sends FTSE 100 spiraling

LONDON, March 23 Mounting fears of a global trade war after the U.S. slapped tariffs on imports from China sent British stocks to a fresh 15-month low on Friday, erasing all the gains the UK's leading stock index made in 2017.

23 Mar 2018

Indivior to fight U.S. court ruling in favour of competitor drug

LONDON, March 23 Britain's Indivior, the maker of opioid addiction treatment Suboxine Film, said it would fight a U.S. court ruling in favour of would-be generic competitor Alvogen that could pave the way to the launch of a rival to its major product.

23 Mar 2018

BRIEF-Indivior Says ‍U.S. Court Found Alvogen Does Not Infringe Claims Of Certain U.S. Patent​s

* ‍RESPONDS TO COURT RULING IN ANDA LITIGATION AND ANNOUNCES INTENTION TO APPEAL

23 Mar 2018

BRIEF-Indivior Says Sublocade Made Available In U.S​

* ‍SUBLOCADE IS NOW AVAILABLE AS FIRST AND ONLY MONTHLY INJECTABLE BUPRENORPHINE IN U.S. TO TREAT PATIENTS WITH MODERATE TO SEVERE OPIOID USE DISORDER​​ Source text for Eikon: Further company coverage:

01 Mar 2018

Earnings vs. Estimates